Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

1.

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM.

Neoplasia. 2013 Aug;15(8):975-88.

PMID:
23908597
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.

Konecny GE, Kolarova T, O'Brien NA, Winterhoff B, Yang G, Qi J, Qi Z, Venkatesan N, Ayala R, Luo T, Finn RS, Kristof J, Galderisi C, Porta DG, Anderson L, Shi MM, Yovine A, Slamon DJ.

Mol Cancer Ther. 2013 May;12(5):632-42. doi: 10.1158/1535-7163.MCT-12-0999. Epub 2013 Feb 26.

PMID:
23443805
[PubMed - indexed for MEDLINE]
Free Article
3.

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.

Byron SA, Loch DC, Pollock PM.

Int J Gynecol Cancer. 2012 Nov;22(9):1517-26. doi: 10.1097/IGC.0b013e31826f6806.

PMID:
23060048
[PubMed - indexed for MEDLINE]
4.

Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.

Eritja N, Domingo M, Dosil MA, Mirantes C, Santacana M, Valls J, Llombart-Cussac A, Matias-Guiu X, Dolcet X.

Mol Cancer Ther. 2014 Apr;13(4):776-87. doi: 10.1158/1535-7163.MCT-13-0794. Epub 2014 Jan 21.

PMID:
24448819
[PubMed - indexed for MEDLINE]
5.

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.

Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM.

Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7.

PMID:
23468082
[PubMed - indexed for MEDLINE]
6.

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.

Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C.

Mol Cell Endocrinol. 2013 Sep 5;377(1-2):1-6. doi: 10.1016/j.mce.2013.06.025. Epub 2013 Jun 27.

PMID:
23811235
[PubMed - indexed for MEDLINE]
7.

Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.

Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Clackson T, Rivera VM.

Mol Cancer Ther. 2012 Mar;11(3):690-9. doi: 10.1158/1535-7163.MCT-11-0450. Epub 2012 Jan 11.

PMID:
22238366
[PubMed - indexed for MEDLINE]
Free Article
8.

Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.

André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J.

Clin Cancer Res. 2013 Jul 1;19(13):3693-702. doi: 10.1158/1078-0432.CCR-13-0190. Epub 2013 May 8.

PMID:
23658459
[PubMed - indexed for MEDLINE]
Free Article
9.

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.

Cassuto O, Dufies M, Jacquel A, Robert G, Ginet C, Dubois A, Hamouda A, Puissant A, Luciano F, Karsenti JM, Legros L, Cassuto JP, Lenain P, Auberger P.

Oncotarget. 2012 Dec;3(12):1557-65.

PMID:
23238683
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J, Tyner JW, Wong M, Druker BJ.

Blood. 2014 Mar 6;123(10):1516-24. doi: 10.1182/blood-2013-07-518381. Epub 2014 Jan 9.

PMID:
24408322
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.

Zhang H, Hylander BL, LeVea C, Repasky EA, Straubinger RM, Adjei AA, Ma WW.

Br J Cancer. 2014 Jan 21;110(2):320-9. doi: 10.1038/bjc.2013.754. Epub 2013 Dec 10.

PMID:
24327018
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.

Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H.

Invest New Drugs. 2012 Aug;30(4):1352-60. doi: 10.1007/s10637-011-9699-0. Epub 2011 Jun 8.

PMID:
21655918
[PubMed - indexed for MEDLINE]
13.

Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).

Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.

PLoS One. 2013 Oct 4;8(10):e76551. doi: 10.1371/journal.pone.0076551. eCollection 2013.

PMID:
24124571
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

Smith CC, Lasater EA, Zhu X, Lin KC, Stewart WK, Damon LE, Salerno S, Shah NP.

Blood. 2013 Apr 18;121(16):3165-71. doi: 10.1182/blood-2012-07-442871. Epub 2013 Feb 21.

PMID:
23430109
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.

Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T, Dalgarno DC, Zhu X.

Chem Biol Drug Des. 2011 Jan;77(1):1-11. doi: 10.1111/j.1747-0285.2010.01054.x. Epub 2010 Nov 30.

PMID:
21118377
[PubMed - indexed for MEDLINE]
16.

Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.

Jin Y, Ding K, Li H, Xue M, Shi X, Wang C, Pan J.

Mol Cancer. 2014 Jan 28;13:17. doi: 10.1186/1476-4598-13-17.

PMID:
24472312
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.

Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM.

Cancer Res. 2008 Sep 1;68(17):6902-7. doi: 10.1158/0008-5472.CAN-08-0770. Erratum in: Cancer Res. 2008 Dec 1;68(23):10005.

PMID:
18757403
[PubMed - indexed for MEDLINE]
Free Article
18.

Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.

Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, Böhmer FD, Hochhaus A, Fischer T, Scholl S.

Br J Haematol. 2012 May;157(4):483-92. doi: 10.1111/j.1365-2141.2012.09085.x. Epub 2012 Mar 13.

PMID:
22409268
[PubMed - indexed for MEDLINE]
19.

FGFR2 as a molecular target in endometrial cancer.

Byron SA, Pollock PM.

Future Oncol. 2009 Feb;5(1):27-32. doi: 10.2217/14796694.5.1.27. Review.

PMID:
19243295
[PubMed - indexed for MEDLINE]
20.

Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.

De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M.

J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22.

PMID:
23526464
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk